| 1 |
Llovet JM.Evidence-based medicine in the treatment of hepatocellular carcinoma.J Gastroenterol Hepatol,2002,17 Suppl 3:S428-433.
|
| 2 |
Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma- an updated analysis of randomized controlled trials. Aliment Pharmacol Ther,2006,23(11):1535-1547.
|
| 3 |
Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 2008,100(10):698-711.
|
| 4 |
Yamazaki S,Takayama T.Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. World J Gastroenterol, 2008, 14(5):685-692.
|
| 5 |
Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine(PDQ)[EB/OL]. [2002-02-10]. http://www.cancer.gov/cancertopics/pdq/levels-evidence-cam/HealthProfessional/pag e2.
|
| 6 |
Llovet JM, Fuster J, Bruix J. Intentionto-treat analysis of surgical treat ment for early hepatocellular carcinoma: resection versus transplantation.Hepatology,1999;30(6):1434-1440.
|
| 7 |
Llovet JM,Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis, 2005, 25(2):181-200.
|
| 8 |
Schwartz JD,Schwartz M,Mandeli J,et al.Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomized clinical trials.Lancet Oncol,2002,3(10):593-603.
|
| 9 |
Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma.Ann Surg,2003,238(5):703-710.
|
| 10 |
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med,1996,334(11):693-699.
|
| 11 |
Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.Hepatology,2004,40(6):1352-1360.
|
| 12 |
Arii S,Yamaoka Y,Futagawa S,et al.Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology, 2000, 32(6):1224-1229.
|
| 13 |
Bruix J,Sala M,Llovet JM.Chemoembolization for hepatocellular carc inoma.Gastroenterology,2004,127(5 Suppl 1):S179-188.
|
| 14 |
Llovet JM,Real MI,Montana X,et al.Arterial embolisation or chemoe mbolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet,2002,359(9319):1734-1739.
|
| 15 |
Llovet JM,Bruix J.Systematic review of randomized trials for unresec table hepatocellular carcinoma:chemoembolization improves survival.Hepatology,2003,37(2):429-442.
|
| 16 |
Lo CM,Ngan H,Tso WK,et al. Randomized controlled trial of transa rterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.Hepatology,2002,35(5):1164-1171.
|
| 17 |
Raoul JL,Guyader D,Bretagne JF,et al.Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology,1997,26(5):1156-1161.
|
| 18 |
Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma.Expert Opin Investig Drugs,2004,13(12):1555-1568.
|
| 19 |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma.N Engl J Med,2008,359(4):378-390.
|